Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Cerevel Therapeutics Holdings Inc shares valued at $2,050,550 were sold by COLES N ANTHONY on Mar 04 ’24. At $41.01 per share, COLES N ANTHONY sold 50,000 shares. The insider’s holdings dropped to 15,638 shares worth approximately $0.66 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, COLES N ANTHONY sold 50,000 shares, netting a total of over 2,057,890 in proceeds. Following the sale of shares at $41.16 each, the insider now holds 15,638 shares.
Before that, COLES N ANTHONY had sold 2,506 shares from its account. In a trade valued at $104,110, the Director traded Cerevel Therapeutics Holdings Inc shares for $41.54 each. Upon closing the transaction, the insider’s holdings decreased to 2,506 shares, worth approximately $0.66 million.
As published in a research note from TD Cowen on December 08, 2023, Cerevel Therapeutics Holdings Inc [CERE] has been rated down from an Outperform to a Market perform and the price target has been revised to $45. As of September 28, 2023, Piper Sandler has initiated its “an Overweight” rating for CERE. Earlier on August 03, 2023, BofA Securities downgraded its rating. Their new recommendation was “a Neutral” for CERE stock which previously was a “a Buy”.
Analyzing CERE Stock Performance
During the last five days, there has been a surge of approximately 0.07%. Over the course of the year, Cerevel Therapeutics Holdings Inc shares have dropped approximately -0.31%. Shares of the company reached a 52-week high of $43.59 on 02/15/24 and a 52-week low of $40.66 on 02/22/24. A 50-day SMA is recorded $41.94, while a 200-day SMA reached $31.67. Nevertheless, trading volume fell to 0.74 million shares from 1.58 million shares the previous day.
Support And Resistance Levels for Cerevel Therapeutics Holdings Inc (CERE)
According to the 24-hour chart, there is a support level at 42.16, which, if violated, would cause prices to drop to 42.05. In the upper region, resistance lies at 42.43. The next price resistance is at 42.58. RSI (Relative Strength Index) is 60.06 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.47, which suggests the price will decrease in the coming days. Percent R is at 26.32%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Cerevel Therapeutics Holdings Inc subject to short interest?
Stocks of Cerevel Therapeutics Holdings Inc saw a sharp rise in short interest on Feb 29, 2024 jumping by 1.08 million shares to 7.1 million. Data from Yahoo Finance shows that the short interest on Jan 31, 2024 was 6.02 million shares. A jump of 15.21% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.18 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.18.
